300149.SZ
ChemPartner PharmaTech Co., Ltd.
SZSE · M 科研服务 · CN
CNY 9.70
−6.55%Year over year
Reported trailing growth
- Revenue
- +14.4%
- EBITDA
- —
- EBIT
- +94.7%
- EPS
- +93.7%
- Free cash flow
- +41.1%
- Operating cash flow
- +44.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -5.1%
- EBITDA
- -49.0%
- EBIT
- -68.6%
- Net income
- -66.7%
- EPS
- -65.5%
- Free cash flow
- +29.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026